Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jan 11, 2016

166_ip_2016-01-11_32cee464-b6db-4d24-9cf3-967eae6f1671.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

A LEADING GLOBAL HEALTH CARE GROUP

Frankfurt Stock Exchange (DAX30): FRE │ US ADR program (OTC): FSNUY │ wwww.fresenius.com/investors

SAFE HARBOR STATEMENT

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

A GLOBAL LEADER IN HEALTH CARE PRODUCTS AND SERVICES

FINANCIAL RESULTS – AN EXCELLENT LONG-TERM TRACK RECORD

TOTAL SHAREHOLDER RETURN

CAGR, ROUNDED

Source: Bloomberg; dividends reinvested

STRONG, DIVERSIFIED PRODUCT AND SERVICE PORTFOLIO

FRESENIUS MEDICAL CARE: GLOBAL DIALYSIS MARKET LEADER

  • The world's leading provider of dialysis products and services treating >290,000 patients in 3,400 clinics1
  • Provide highest standard of product quality and patient care

Expansion in Care Coordination and global dialysis service opportunities; enter new geographies

Market Dynamics

Global Dialysis Market 2014: ~US\$77 bn; ~6% patient growth p.a.

Growth Drivers: Aging population, increasing incidence of diabetes and high blood pressure, treatment quality improvements

FRESENIUS KABI: A LEADING GLOBAL HOSPITAL SUPPLIER

  • Comprehensive product portfolio for critically and chronically ill patients
  • Strong Emerging Markets presence
  • Leading market positions in four product segments

Focus on organic growth through geographic product rollouts and new product launches

Market Dynamics

Global Addressable Market 2014: >€29 bn

Growth Drivers: Patent expirations, rising demand for health care services, higher health care spending in Emerging Markets

FRESENIUS HELIOS: LEADING GERMAN HOSPITAL OPERATOR

  • ~6% share in German acute care hospital market
  • Strong track record in hospital acquisitions and operations
  • High-quality medical care, e.g., mortality rate for heart failure and pneumonia below German average
  • Comprehensive healthcare services coverage

1 German Federal Statistical Office 2014; total costs, gross of the German hospitals less academic research and teaching

Market Dynamics

German Acute Care Hospital Market: ~€87 bn1

Growth Drivers: Aging population leading to increasing hospital admissions, further market consolidation

Majority of population has access to a HELIOS hospital within one hour's drive1

  • 111 hospitals

  • 34,000 beds

  • ~1.2 million inpatient admissions
  • ~3.3 million outpatient admissions

1 As of Sep 30, 2015

FRESENIUS VAMED:

LEADING GLOBAL HOSPITAL PROJECTS AND SERVICES SPECIALIST

Manages hospital construction/expansion projects (54% of sales) and provides services (46% of sales) for health care facilities worldwide

  • Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
  • Strong track record: More than 710 projects in 77 countries completed

Market Dynamics

Growth Drivers:

Emerging Market demand for building and developing hospital infrastructure

Outsourcing of non-medical services from public to private operators

INVESTMENT HIGHLIGHTS

SHARE INFORMATION

Share key facts

5
4
5,
7
2
7,
9
5
0
8
/
8
5
7
5
6
0
D
E
0
0
0
5
7
5
6
0
4
F
R
E
F
R
E
G
R
d
F
R
E
G
e

ADR key facts

R
t
i
a
o		 d
h
4
A
D
R
1
i
s
o
r
n
a
r
y
s
a
r
e
=
A
D
R
C
U
S
I
P
/
I
S
I
N		 3
5
8
0
4
M
1
0
5
/
U
S
3
5
8
0
4
M
1
0
5
3
k
b
l
T
i
c
e
r
s
y
m
o		 F
S
N
U
Y
h
E
c
a
n
g
e
x		 l
O
T
C
Q
X
I
i
P
i
t
t
n
e
n
a
o
n
a
e
m
e
r
r
r
S
t
t
c
e
r
u
u
r		 d
l
S
L
I
A
D
R
p
o
n
s
o
e
e
e
r
v
b
k
D
i
t
e
p
o
s
a
r
y
a
n		 h
k
D
t
B
e
u
s
c
e
a
n

FINANCIAL CALENDAR 2016

2
4
0
2
2
0
1
6		 R
F
Y
2
0
1
5
t
e
p
o
o
n
r
0
3
0
2
0
1
6
5		 t
1
2
0
1
6
R
t
t
s
e
p
o
o
n
q
a
e
r
u
r
r
1
3
0
2
0
1
6
5		 l
l
k
f
/
G
i
i
A
M
t
F
t
M
n
n
a
e
n
e
a
e
e
n
g
a
n
a
n
u
r
r
u
r
,
0
2
0
8
2
0
1
6		 d
2
2
0
1
6
R
t
t
n
e
p
o
o
n
q
a
e
r
u
r
r
2
1
0
2
0
1
6
7		 d
3
2
0
1
6
R
t
t
r
e
p
o
o
n
q
a
e
r
u
r
r

Please note that these dates could be subject to change.

CONTACT

Investor RelationsFresenius SE & Co. KGaA

phone: +49 6172 608-2487 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.